AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06706245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-VR (headset)
Description: High-immersive version of the SET-VR program
Study NCT06706687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DISBAND protocol
Description: For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
Study NCT06704360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immersive VR pathfinding training
Description: Pathfinding training with immersive VR.
Study NCT06704360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Only receive conventional cognitive training group
Study NCT06704711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine 300 MG
Description: They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.
Study NCT06704711 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
Study NCT06704711 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
Study NCT06704711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will rinse 20 mL of distilled water in their mouth for 20 seconds.
Study NCT05135000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTP001
Description: LTP001 will be administered orally once daily in the morning
Study NCT05135000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LTP001 will be administered once daily in the morning
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib
Description: tablet, oral
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LoDAC
Description: subcutaneous (SC) or intravenous (IV) injection
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: SC or IV
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: IV
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C±IDA
Description: SC and IV
Study NCT05586074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG-IDA
Description: SC and IV
Study NCT02503189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution
Study NCT02503189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05888038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality
Study NCT05467527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice
Description: The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
Study NCT05467527 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive parenting advice
Description: The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
Study NCT05452863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic administered oxygen
Description: Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
Study NCT05452863 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual oxygen supply and adjustments
Description: Oxygen supply is adjusted from manual measurements of the oxygen saturation
Study NCT03105713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Safety Checklist
Description: The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
Study NCT05784844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Carbapenem antibiotic
Study NCT05784844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Echinocandin antifungal
Study NCT05296018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring page
Description: Mandala program will be applied three days a week (30 minutes) for 8 weeks.
Study NCT04890860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
Description: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
Study NCT05155280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET imaging using [11C]DASB radioligand.
Description: Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
Study NCT05155280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging using [11C]DASB radioligand.
Description: Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
Study NCT05155280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Tracker
Description: The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach.
Study NCT05155280 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eye Tracker
Description: The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach.
Study NCT05923125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded-Intensity Treadmill Exercise Protocol
Description: The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
Study NCT05849142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRIdian Linac
Description: Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
Study NCT06185816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment
Description: The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
Study NCT06185816 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active Treatment
Description: The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
Study NCT06001047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
Study NCT06001047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol.
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK Inhibitor
Description: Given PO
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04370301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given SC
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Given IV
Study NCT04370301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04370301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04370301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06600347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
Study NCT06600347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
Study NCT05688345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
Study NCT05688345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
Study NCT05688345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
Study NCT05209763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More intensive rehabilitation
Description: Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
Study NCT05209763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: More intensive rehabilitation
Description: Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
Study NCT05209763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: More intensive nutrition
Description: in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses
Study NCT05209763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: More intensive nutrition
Description: in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses
Study NCT06600347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive drugs
Description: All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WL & exercise
Description: Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WL & no exercise
Description: Intake of DGA weight loss 8 day rotating menu \& no exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WM & exercise
Description: Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WM & no exercise
Description: Intake of DGA weight maintenance 8 day rotating menu \& no exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WL & exercise
Description: Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WL & no exercise
Description: Intake of Western-type weight loss 8 day rotating menu \& no exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WM & exercise
Description: Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise
Study NCT04577547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WM & no exercise
Description: Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
Study NCT04574050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SELF-BREATHE
Description: A self -guided, internet -based intervention for patients with chronic breathlessness
Study NCT04595968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal DM Active device
Description: Battery powered non-invasive neurostimulation device
Study NCT04595968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
Study NCT04595968 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle modification
Description: Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
Study NCT04595968 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vestal DM Sham device
Description: Placebo comparator sham device (no active stimulation)
Study NCT06190158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral sodium suppression test
Description: Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
Study NCT06190158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saline suppression test
Description: Saline suppression test (2 liters of saline)
Study NCT06190158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Captopril suppression test
Description: Captopril suppression test (50mg of captopril)
Study NCT06190158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone suppression test
Description: 1mg of dexamethasone
Study NCT06190158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cosyntropin stimulation test
Description: 250mcg of cosyntropin
Study NCT06281756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: Subjects will receive therapy for 8 weeks
Study NCT06281756 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: Subjects will receive therapy for 8 weeks
Study NCT06281756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
Study NCT06281756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-remitting subjects will receive placebo for 8 weeks
Study NCT06498583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.25 % ropivacaine ( 0.5ml / kg )